P. Miele, Truvada (emtricitabine-tenofovir disoproxil fumarate) preexposure prophylaxis indication for prevention of sexually acquired HIV-1. Antiviral drugs advisory committee meeting, pp.21-752

J. Colbert, Preexposure Prophylaxis for HIV Prevention ??? Polling Results, New England Journal of Medicine, vol.367, issue.15, p.22, 2012.
DOI : 10.1056/NEJMclde1211517

D. Krakower, M. Mimiaga, and J. Rosenberger, Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking Site, PLoS ONE, vol.24, issue.3, p.33119, 2012.
DOI : 10.1371/journal.pone.0033119.t005

L. Vu, S. , L. Strat, Y. Barin, and F. , Population based HIV incidence in France 2003?08: a modelling analysis, Lancet Infect Dis, vol.10, pp.682-687, 2010.

P. Birrel, O. Gill, and V. Delpech, HIV incidence in men who have sex with men in England and Wales 2001???10: a nationwide population study, The Lancet Infectious Diseases, vol.13, issue.4, pp.313-318, 2013.
DOI : 10.1016/S1473-3099(12)70341-9

L. Vu, S. Velter, A. Meyer, and L. , Biomarker-based HIV incidence in a community sample of men who have sex with men in Paris, France. PLoS One, vol.7, p.39872, 2012.

R. Grant, J. Lama, P. Anderson, . Iprex-study, and . Team, Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men, New England Journal of Medicine, vol.363, issue.27, pp.2587-2599, 2010.
DOI : 10.1056/NEJMoa1011205

J. Baeten, D. Donnell, and P. Ndase, Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women, New England Journal of Medicine, vol.367, issue.5, pp.399-410, 2012.
DOI : 10.1056/NEJMoa1108524

M. Thigpen, P. Kebaabetswe, and L. Paxton, Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana, New England Journal of Medicine, vol.367, issue.5, pp.423-434, 2012.
DOI : 10.1056/NEJMoa1110711

L. Van-damme, A. Corneli, and K. Ahmed, Preexposure Prophylaxis for HIV Infection among African Women, New England Journal of Medicine, vol.367, issue.5, pp.411-422, 2012.
DOI : 10.1056/NEJMoa1202614

J. Marrazzo, G. Ramjee, and G. Nair, Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir ge in the VOICE study, Presented at the 20th Conference on Retroviruses and Opportunistic Infections, p.26, 2013.

K. Choopanya, M. Martin, and P. Suntharasamai, Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial, The Lancet, vol.381, issue.9883, pp.2083-2090, 2013.
DOI : 10.1016/S0140-6736(13)61127-7

A. Stone, Regulatory issues in microbicide development Switzerland: World Health Organization, Geneva

B. Haire, J. Kaldor, and C. Jordens, How Good Is ???Good Enough???? The Case for Varying Standards of Evidence According to Need for New Interventions in HIV Prevention, The American Journal of Bioethics, vol.3, issue.3, pp.21-30, 2012.
DOI : 10.1056/NEJM199710023371411

L. Bekker, D. Glidden, and S. Hosek, Pre-exposure prophylaxis in young MSM: needs and challenges, Presented at the 20th Conference on Retroviruses and Opportunistic Infections, p.997, 2013.

K. Patterson, H. Prince, and E. Kraft, Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission, Science Translational Medicine, vol.3, issue.112, pp.112-116, 2011.
DOI : 10.1126/scitranslmed.3003174

J. Hughes, J. Baeten, and J. Lingappa, Determinants of Per-Coital-Act HIV-1 Infectivity Among African HIV-1-Serodiscordant Couples, Journal of Infectious Diseases, vol.205, issue.3, pp.358-365, 2012.
DOI : 10.1093/infdis/jir747

K. Mlisana, N. Naicker, and L. Werner, Symptomatic Vaginal Discharge Is a Poor Predictor of Sexually Transmitted Infections and Genital Tract Inflammation in High-Risk Women in South Africa, Journal of Infectious Diseases, vol.206, issue.1, pp.6-14, 2012.
DOI : 10.1093/infdis/jis298

A. Liu, E. Vittinghoff, and D. Sellmeyer, Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco, PLoS ONE, vol.51, issue.8, p.23688, 2011.
DOI : 10.1371/journal.pone.0023688.s002

J. Pavie, A. Rachline, and B. Loze, Sensitivity of Five Rapid HIV Tests on Oral Fluid or Finger-Stick Whole Blood: A Real-Time Comparison in a Healthcare Setting, PLoS ONE, vol.4, issue.19, p.11581, 2010.
DOI : 10.1371/journal.pone.0011581.t005

J. Juusola, M. Brandeau, D. Owens, and E. Bendavid, The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men, Annals of Internal Medicine, vol.156, issue.8, pp.541-550, 2012.
DOI : 10.7326/0003-4819-156-8-201204170-00004

G. Gomez, A. Borquez, and C. Caceres, The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study, PLoS Medicine, vol.9, issue.10, p.1001323, 2012.
DOI : 10.1371/journal.pmed.1001323.s015

P. Adam, A. Alexandre, and J. De-wit, Perception de la prophylaxie pré-exposition (PrEP) par les internautes gays français

N. Ware, M. Wyatt, and J. Haberer, What??s Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant Couples, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.59, issue.5, pp.463-468, 2012.
DOI : 10.1097/QAI.0b013e31824a060b

S. Hosek, G. Siberry, and M. Bell, The Acceptability and Feasibility of an HIV Preexposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.62, issue.4, pp.447-456, 2013.
DOI : 10.1097/QAI.0b013e3182801081

R. Grant, V. Mcmahan, and R. Amico, Drug detection during open-label extension of the iPrEx trial indicates sustained and appropriate interest in PrEP among men who have sex with men. Presented at the 7th IAS Conference on HIV Pathogenesis treatment and Prevention. Kuala Lumpur Malaysia: Abstract WELBC02, 2013.

J. Castillo-mancilla, J. Zheng, and J. Rower, Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure, AIDS Research and Human Retroviruses, vol.29, pp.384-390, 2013.
DOI : 10.1089/aid.2012.0089

S. Shah, R. Mullin, and G. Jones, Simultaneous analysis of antiretroviral drugs abacavir and tenofovir in human hair by liquid chromatography???tandem mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, vol.74, pp.308-313, 2013.
DOI : 10.1016/j.jpba.2012.10.023

J. García-lerma, M. Cong, and J. Mitchell, Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection, Science Translational Medicine, vol.2, issue.14, pp.14-18, 2010.
DOI : 10.1126/scitranslmed.3000391

A. The and . Study, Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP). http://clinicaltrials.gov/show, 1327651.

A. Karim, Q. , A. Karim, S. Frohlich, and J. , Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women, Science, vol.329, issue.5996, pp.1168-1174, 2010.
DOI : 10.1126/science.1193748

N. Lorente, L. Fugon, and M. Carrieri, Acceptability of an ???on-demand??? pre-exposure HIV prophylaxis trial among men who have sex with men living in France, AIDS Care, vol.14, pp.468-477, 2012.
DOI : 10.1186/1758-2652-13-13

J. Volk, A. Liu, and E. Vittinghoff, Sexual Frequency and Planning Among At-Risk Men Who Have Sex With Men in the United States, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.61, issue.1, pp.112-115, 2012.
DOI : 10.1097/QAI.0b013e31825bd87d

S. Hosek, K. Telander, and C. Balthazar, Does sexual behaviour influence adherence to pre-exposure prohylaxis? Data from a pre-exposure prophylaxis trial among young MSM, Presented at the 20th Conference on Retroviruses and Opportunistic Infections, p.996, 2013.

P. Anderson, D. Glidden, and A. Liu, Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men, Science Translational Medicine, vol.4, issue.151, pp.151-125, 2012.
DOI : 10.1126/scitranslmed.3004006

G. Van-'t-klooster, E. Hoeben, and H. Borghys, Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation, Antimicrobial Agents and Chemotherapy, vol.54, issue.5, pp.2042-2050, 2010.
DOI : 10.1128/AAC.01529-09

C. Andrews, A. Gettie, and K. Russel-lodrigue, Long-acting parenteral formulation of GSK1265744 protects macaques against repeated intrarectal challenges with SHIV, Presented at the 20th Conference on Retroviruses and Opportunistic Infections, p.24, 2013.

S. Mccormack, S. Fidler, and M. Fisher, The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK, International Journal of STD & AIDS, vol.35, issue.1, pp.1-4, 2012.
DOI : 10.1097/QAD.0b013e32832b7dca

. Molina, Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?, BMC Medicine, vol.23, issue.1, p.186, 2013.
DOI : 10.1258/ijsa.2011.051211
URL : https://hal.archives-ouvertes.fr/inserm-00903749